Big Win for Indian Pharma in U.S. Trade Policy!

Despite new tariffs on Indian imports, pharmaceuticals have been exempted from additional duties under the latest U.S. trade measures. 🇮🇳➡️🇺🇸

💊 Why does this matter?
🔹 India supplies 47% of the U.S. generic drug market, ensuring access to affordable medicines.
🔹 Pharma exports to the U.S. stood at $8.7 billion in FY 2023-24, reinforcing India’s role as the “pharmacy of the world.”
🔹 Stocks of major Indian pharma companies—Sun Pharma, Cipla, Lupin—surged 3.4-4.2% post-announcement.

This move signals the strategic importance of Indian generics in U.S. healthcare and presents a golden opportunity for Indian pharma to strengthen its foothold by focusing on quality, innovation, and compliance.

A win-win for both nations! 🌍💊